Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials

The Lancet Respiratory Medicine 2026

View at publisher
Authors: Alberto Papi, Robert Wise, David J Jackson, Njira Lugogo, Ruchong Chen, Teodora Trasieva, Chidi Obasi, Charlotta Movitz, Jesse Helman, Patricia Salter, Katarzyna Springer, Marco Bondoc
+6 more Mihir Shah, Katharine Knappenberger, Karin Bowen, Hitesh Pandya, Ayman Megally, Mehul Patel
DOI: 10.1016/s2213-2600(25)00457-6
Cited by: 5
References: 15

Fields of Study & Subjects

Asthma and respiratory diseases Drug-Induced Adverse Reactions Pharmacological Effects and Assays

Publication details

Journal / source
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Volume
14
Issue
4
Pages
350–362
Publication date
13 February 2026
Language
EN